just had a good watch of the webinar. A little hidden gem in there imo. He mentioned a slower increase of myo-inositol for the (earlier stage) responders. As myo-inositol is associated with increased tapping in PD, if the 201 shows a stabilisation of this sugar (reasonable assumption imo as 434 looks it has more efficacy in earlier stage) you would think pharma and MJFF would be very interested in this. This was quietly mentioned in the talk with the foundation being interested in the biomarker data.
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-159
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $1.528K | 317.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 102 | 97511267 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 31179254 | 15 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |